Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University, Seongnam, South Korea.
Department of Nuclear Medicine, Seoul National University Hospital, Seoul, South Korea.
Eur J Nucl Med Mol Imaging. 2017 Nov;44(12):1995-2003. doi: 10.1007/s00259-017-3755-8. Epub 2017 Jun 20.
F-Fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) has been investigated as a method to predict pancreatic cancer recurrence after pancreatic surgery. We evaluated the recently introduced heterogeneity indices of F-FDG PET/CT used for predicting pancreatic cancer recurrence after surgery and compared them with current clinicopathologic and F-FDG PET/CT parameters.
A total of 93 pancreatic ductal adenocarcinoma patients (M:F = 60:33, mean age = 64.2 ± 9.1 years) who underwent preoperative F-FDG PET/CT following pancreatic surgery were retrospectively enrolled. The standardized uptake values (SUVs) and tumor-to-background ratios (TBR) were measured on each F-FDG PET/CT, as metabolic parameters. Metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were examined as volumetric parameters. The coefficient of variance (heterogeneity index-1; SUVmean divided by the standard deviation) and linear regression slopes (heterogeneity index-2) of the MTV, according to SUV thresholds of 2.0, 2.5 and 3.0, were evaluated as heterogeneity indices. Predictive values of clinicopathologic and F-FDG PET/CT parameters and heterogeneity indices were compared in terms of pancreatic cancer recurrence.
Seventy patients (75.3%) showed recurrence after pancreatic cancer surgery (mean recurrence = 9.4 ± 8.4 months). Comparing the recurrence and no recurrence patients, all of the F-FDG PET/CT parameters and heterogeneity indices demonstrated significant differences. In univariate Cox-regression analyses, MTV (P = 0.013), TLG (P = 0.007), and heterogeneity index-2 (P = 0.027) were significant. Among the clinicopathologic parameters, CA19-9 (P = 0.025) and venous invasion (P = 0.002) were selected as significant parameters. In multivariate Cox-regression analyses, MTV (P = 0.005), TLG (P = 0.004), and heterogeneity index-2 (P = 0.016) with venous invasion (P < 0.001, 0.001, and 0.001, respectively) demonstrated significant results.
The heterogeneity index obtained using the linear regression slope, could be an effective predictor of pancreatic cancer recurrence after pancreatic cancer surgery, in addition to F-FDG PET/CT volumetric parameters and clinicopathologic parameters.
氟代脱氧葡萄糖(FDG)正电子发射断层扫描(PET)/计算机断层扫描(CT)已被研究作为预测胰腺手术后胰腺癌复发的一种方法。我们评估了最近引入的用于预测胰腺手术后胰腺癌复发的 F-FDG PET/CT 异质性指数,并将其与当前的临床病理和 F-FDG PET/CT 参数进行了比较。
回顾性纳入了 93 例接受胰腺手术后行 F-FDG PET/CT 检查的胰腺导管腺癌患者(M:F=60:33,平均年龄 64.2±9.1 岁)。在每次 F-FDG PET/CT 上测量标准化摄取值(SUV)和肿瘤与背景比值(TBR)作为代谢参数。代谢肿瘤体积(MTV)和总病变糖酵解(TLG)作为体积参数进行检查。根据 SUV 阈值为 2.0、2.5 和 3.0,评估 MTV 根据 SUV 测量值的异质性指数-1(SUVmean 除以标准差)和线性回归斜率(异质性指数-2)。比较临床病理和 F-FDG PET/CT 参数和异质性指数的预测值,以评估胰腺癌复发情况。
70 例患者(75.3%)在胰腺手术后出现复发(平均复发时间为 9.4±8.4 个月)。与复发和未复发患者相比,所有 F-FDG PET/CT 参数和异质性指数均有显著差异。在单因素 Cox 回归分析中,MTV(P=0.013)、TLG(P=0.007)和异质性指数-2(P=0.027)有统计学意义。在临床病理参数中,CA19-9(P=0.025)和静脉侵犯(P=0.002)为显著参数。在多因素 Cox 回归分析中,MTV(P=0.005)、TLG(P=0.004)和异质性指数-2(P=0.016)与静脉侵犯(P<0.001、0.001 和 0.001)有统计学意义。
除 F-FDG PET/CT 体积参数和临床病理参数外,使用线性回归斜率获得的异质性指数可有效预测胰腺手术后胰腺癌的复发。